.png)
Capital Rx
Highlights
- One key new drug approval: Xolremdi™ capsules to tread WHIM syndrome
- One notable expanded indication: Rinvoq® to treat psoriatic arthritis in patients >2yo
- Two generic launches
- Capital Rx's Updated Drug Recall Report: CLICK HERE to review
Capital Rx's Clinical Team closely monitors the drug landscape to provide our clients with timely information on newly FDA-approved medications, as well as products in the pipeline. Read on to review our May 2024 Monthly Drug Update!
Key New Drug Approvals
Xolremdi™ (mavorixafor) capsules
Approval Date: 04/26/2024 - CLICK HERE for the press release
Indication: Treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis) in patients 12 years of age and older
Cost*: $31,000 - $41,000 monthly
Key Considerations:
- First drug approved for WHIM syndrome
- Received priority review
- Orphan drug designation
Notable Expanded Indications
Rinvoq® (upadacitinib) – expanded to treat psoriatic arthritis in patients 2 years of age and older
Generic Launches
EstroGel® (estradiol 0.06%) gel
Myrbetriq® (mirabegron ER 24hr 50 mg) tablet
Contact Us if you'd like to learn more about Capital Rx's full-service pharmacy benefit management (PBM) solutions and clinical programs.
--------
* Cost: actual patient out-of-pocket costs may be lower, as the list price does not reflect insurance coverage, co-pay support for eligible patients, or financial assistance from patient support